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Aims: We have isolated a new muscarinic protein (MT-Mlα) from the venom of the Brazilian coral snake
Micrurus lemniscatus.
Main methods: This small protein, which had a molecular mass of 7,048 Da, shared high sequence homology
with three-ﬁnger proteins that act on cholinergic receptors. The ﬁrst 12 amino acid residues of the
N-terminal sequence were determined to be: Leu-Ile-Cys-Phe-Ile-Cys-Phe-Ser-Pro-Thr-Ala-His.
Key ﬁndings: The MT-Mlα was able to displace the [3H]QNB binding in the hippocampus of rats. The binding
curve in competition experiments with MT-Mlαwas indicative of two types of [3H]QNB-binding site with pKi
values of 9.08±0.67 and 6.17±0.19, n=4, suggesting that various muscarinic acetylcholine receptor
(mAChR) subtypes may be the target proteins of MT-Mlα. The MT-Mlα and the M1 antagonist pirenzepine
caused a dose-dependent block on total [3H]inositol phosphate accumulation induced by carbachol. The
IC50 values for MT-Mlα and pirenzepine were, respectively, 33.1 and 2.26 nM. Taken together, these stud-
ies indicate that the MT-Mlα has antagonist effect on mAChRs in rat hippocampus.
Signiﬁcance: The results of the present study show, for the ﬁrst time, that mAChRs function is drastically
affected by MT-Mlα since it not only has afﬁnity for mAChRs but also has the ability to inhibit mAChRs.© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Acetylcholine is a major neurotransmitter in the central and
peripheral nervous systems (Caulﬁeld, 1993; Wess et al., 1990).
The nicotinic acetylcholine receptors (nAChRs) are activated by
nicotine and belong to the ligand-gated ion channel superfamily,
whereas muscarinic acetylcholine receptors (mAChRs) are activated
bymuscarine and belong to the family of G-protein-coupled receptors.
The muscarinic actions of acetylcholine are mediated by ﬁve distinct
mAChR subtypes (M1 to M5) (Caulﬁeld, 1993; Caulﬁeld and Birdsall,
1998; Wess, 1996). Different experimental approaches have shown
that mAChRs are present in all organs, tissues or cell types (Caulﬁeld,
1993; Levey, 1993; Vilaro et al., 1993;Wolfe and Yasuda, 1995). Central
mAChRs are involved in regulating a large number of cognitive,
behavioral, sensory, motor and autonomic functions (see Wess, 2004,
for review). In addition, reduced or increased signaling through distinct
mAChR subtypes has been implicated in the pathophysiology of several
major diseases of the central nervous system, including Alzheimer's andlogy, Instituto Butantan, São
00.
dalla).
evier OA license.Parkinson's disease, depression, schizophrenia and epilepsy (Eglen et
al., 1999; Felder et al., 2000; Levine et al., 1999; Wess et al., 1990).
Muscarinic neurotoxins (MTs) from Elapidae venoms have been
puriﬁed mainly from the venom of African green mamba (genus
Dendroaspis) and characterized for their ability to inhibit the binding
of selective muscarinic ligands such as [3H]quinuclidinyl benzilate
([3H]QNB) and [3H]N-methylscopolamine to an enriched source of
mAChRs (Adem et al., 1988; Bradley, 2000; Karlsson et al., 2000;
Kornisiuk et al., 1995; Jolkkonen et al., 1994). Furthermore, MTs
have been reported to possess high afﬁnity for individual mAChR
subtypes (Bradley, 2000; Bradley et al., 2003; Jerusalinsky and Harvey,
1994; Jerusalinsky et al., 2000).
Despite the fact that theMTs belong to a family of toxins containing
three-ﬁnger type structures (Kini, 2002), they present functional
differences and display distinct proﬁles as to their interactions
with the various mAChR subtypes. MTs have a variety of functional
characteristics, with competitive antagonist, allosteric modulator or
even agonist effects (Bradley, 2000; Bradley et al., 2003; Servent and
Fruchart-Gaillard, 2009). In addition to the classical MTs that were
originally isolated from the genus Dendroaspis (Servent and
Fruchart-Gaillard, 2009) other MT-like proteins endowed with PLA2
activity have been puriﬁed fromNaja naja sputatrix, Naja atra (Chinese
cobra) and Crotalus atrox venoms (Huang et al., 2008; Miyoshi and Tu,
932 D.C. da Silva et al. / Life Sciences 89 (2011) 931–9381996; 1999; 2000). Thesemolecules also display afﬁnities for different
mAChR subtypes.
Concerning the venoms of Brazilian snakes of the genus Micrurus
(belong to Elapidae family), they are particularly rich in pre- and
pos-synaptic neurotoxins that have the cholinergic system as their
target of action (Dal Belo et al., 2005; Moreira et al., 2010; Silva et
al., 1991; Vital-Brazil, 1987; Vital-Brazil and Fontana (1983/1984)
However, few investigations have dealt with isolated toxins from
venoms of these snakes. Some neurotoxins endowed of PLA2 activity
(Oliveira et al., 2008) or neurotoxins that have high afﬁnity to nAChRs
(Olamendi-Portugal et al., 2008) have been isolated and characterized
from genus Micrurus. In spite of the low incidence of Coral snake
accidents and the fact that the signs and symptoms caused by
Micrurus sp. envenomation are the result of a progressive blockade
of neuromuscular transmission at the endplates, in severe cases,
death may result from respiratory arrest (Olamendi-Portugal et al.,
2008).
So, once the majority of the symptoms of the Coral snake enven-
omation are due to the involvement of the cholinergic nicotinic system,
the effect of toxins acting on mAChRs has rarely been addressed by
toxinologists. Moreover, MTs are minor components of the Coral
snake venom which may impair the development of such studies.
Although very few toxins targeting G protein-coupled receptors
have been isolated and characterized from Elapidae venoms, MTs,
different from the selective ligands described so far, are able to
discriminate between diverse mAChR subtypes. Thus, their distinct
pharmacological properties become valuable tools to the characteriza-
tion of the structure and function of the peripheral and central nervous
systems.
Taking this into consideration, we have undertaken a search for the
components associated with mAChR in the Brazilian snake Micrurus
lemniscatus venom. In the present work, we described for the ﬁrst time
the presence of a three-ﬁnger neurotoxin isolated from M. lemniscatus
venom (MT-Mlα) with afﬁnity for mAChRs. In the design of this work
we performed the puriﬁcation, molecular mass determination, partial
amino acid sequencing of the MT-Mlα, and characterization of their
effects on the inhibition of the binding of the selective muscarinic ligand
[3H]quinuclidinyl benzilate ([3H]QNB) and inhibition of the [3H]inositol
phosphate accumulation in hippocampus from male rats.
Materials and Methods
Materials
The lyophilized M. lemniscatus crude venom was obtained from
Laboratory of Venomous Animals, Federal University of Bahia, Brazil.
Animals
Male Wistar rats, 3 months old, were maintained on a 12 h light,
12 h dark schedule, at 22°C, with food and water ad libitum. The
experimental procedures were conducted according to guidelines for
the care and use of laboratory animals as approved by the Research
Ethical Committee from Instituto Butantan (protocol nº.613/09).
RP-HPLC puriﬁcation of M. lemniscatus venom
CrudeM. lemniscatus venom (10 mg) was diluted in 5 ml of Milli-Q
water. After ﬁltration in a 0.45-μm ﬁlter (Millipore), 400-μL samples
(800μg) were applied to a C8 reversed-phase column (Shim-Pack;
4.6 mm×250 mm, 5μm particle) coupled to a HP 1100 series HPLC
system. The elution was carried out under a ﬂow rate of 1 mL.min-1,
and monitored at 214 nm. A linear gradient of triﬂuoroacetic acid
(TFA) (solvent A) (0.1% TFA in water) and acetonitrile (solvent B)
(90% acetonitrile+10% A), from 10% to 35% of B over 50 min, was
used to elute proteins. Nineteen peaks were manually collectedaccording to the absorbance (Fig. 1). The peaks 1, 2, 3, 4, 5 and 6
were assayed for their ability to inhibit the binding of selectivemusca-
rinic ligands [3H]quinuclidinyl benzilate. For this bioassay, only peak 6
was active and therefore was selected for further biochemical charac-
terization and the [3H]inositol phosphate measured.
Mass spectrometry
Previously lyophilized samples were dissolved into 50% Acetonitrile
(ACN), containing 0.1% formic acid (FA) and deposited into the 384well
plate of the autosampler for ESI-MS analysis in a MSQ Surveyor mass
system (Thermo Finnigan). Typically, 20 μL sample aliquots were
infused in 50% ACN, 0.1% (FA), under a 50 μL.min-1 constant ﬂow,
in positive ionization. Instrument control, data acquisition and
processing were performed by the XCalibur suite (Thermo Finnigan).
N-terminal sequence determination
For N-terminal sequence determination,MT-Mlαwas re-puriﬁcated
in a C18 RP–HPLC column (SUPELCOSIL-LC-18-DB 15 cm×4.6 mm Cat.
No. 58348) eluted with a 0 to 90% Acetonitrile (ACN JT Baker) gradient
containing 0.1% of Triﬂuoracetic acid (TFA Sigma-Aldrich). Solvent A:
0.1% TFA (in Milli-Q water), solvent B 90%ACN (in 0.1% TFA). To deter-
mine the N-terminus sequence, the puriﬁed protein (500 pmol) was
dissolved in ACN 37%, and submitted to the automated Edman degrada-
tion, using a PPSQ-21A Protein Sequencer, following the manufacturer
instructions and protocols (Shimadzu, Kyoto, Japan). The N-terminal
sequence was analyzed with the Expert Protein Analysis System
(http://www.expasy.org/) and the alignment performed with ClustalW
(http://www.ebi.ac.uk/clustalw/).
[3H]Quinuclidinyl benzilate ([3H]QNB) binding assay
Hippocampus membrane, obtained from 6 animals for each exper-
iment, was prepared as described by Cardoso et al. (2004). Brieﬂy, the
hippocampi were isolated from rats, minced and homogenized in
25 mM Tris–HCl, pH 7.4 (containing 0.3 M sucrose, 5 mM MgCl2,
1 mM EDTA and 1 mM phenylmethylsulfonyl ﬂuoride) with a Ultra-
Turrax homogenizer (T-25, Ika Labortechnik, Staufen, Germany).
The homogenate was centrifuged at 1000×g for 10 min. The super-
natant was ﬁltered through two layers of gauze and then centrifuged
at 100,000×g for 60 min. The ﬁnal 100,000×g pellet was re-suspended
in 1 ml of 25 mM Tris–HCl, pH 7.4 (containing 5 mM MgCl2, 1 mM
EDTA and 1 mM phenylmethylsulfonyl ﬂuoride), using a Dounce
homogenizer and stored at −70°C. All procedures were carried out
at 4°C, and all solutions contained freshly added 1 mM phenyl-
methylsulfonyl ﬂuoride to inhibit proteolysis. Protein concentration
of membrane preparations was determined with a protein reagent
assay (Bio Rad Laboratories Inc., Hercules, CA, USA).
Saturation and competition binding experiments were performed
as described by Abdalla et al. (2000). Brieﬂy, hippocampus membrane
preparation (80 μg protein/ml) was incubated with 0.05 nM to 8.0 nM
[3H]QNB (speciﬁc activity 44 Ci/mmol; New England Nuclear, Boston,
MA, USA) in the absence (total binding) and presence (nonspeciﬁc
binding) of 1 μM atropine (Sigma Chemical Co., St Louis, MO, USA) for
1 h at 30°C. Speciﬁc binding was calculated as the difference between
total and nonspeciﬁc binding. The nonspeciﬁc binding, near the KD
value, was about 10% of the [3H]QNB total binding.
In competition binding experiments, hippocampus membrane
preparation (80 μg protein/ml) was incubated with [3H]QNB (concen-
tration near the KD values) for 1 h at 30°C in the absence and presence
of increasing concentrations of MT-Mlα or atropine as a control of the
assay.
Saturation and competition binding data were analyzed using a
weighted nonlinear least-squares interactive curve-ﬁtting program
GraphPad Prism (GraphPad Prism Software Inc, San Diego, CA, USA).
Minutes
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Vo
lts
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
2,0
Vo
lts
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
2,0
1
2 3
4
5
6
P7 #151-335 RT: 1.31-2.92 AV: 185 NL: 4.30E4
T: {0;0}  + p ESI corona sid=40.00  det=1153.00 Full ms [300.00-2000.00]
700 800 900 1000 1100 1200 1300 1400 1500
m/z
0
10
20
30
40
50
60
70
80
90
100 1008.05
882.17
887.42
1175.81
6200 6400 6600 6800 7000
Mass
7200 7400 7600 7800 8000
793.54
678.78 1067.56934.30714.53 1410.58804.79 1204.941119.31 1272.57 1493.961338.33
[M+7H]+
[M+6H]+
[M+8H]+
[M+9H]+
[M+5H]+
(7048.12±1.78)Da
Fig. 1. Analytical RP-HPLC proﬁle ofMicrurus lemniscatus venom on a C8 column eluted with triﬂuoroacetic acid (0.1%) (solvent A) and acetonitrile (90%+10% A) (solvent B) and a
solvent gradient developed from 10% to 35% of acetonitrile within 50 min, monitored at 214 nm and 0.05 AUFS (absorbance unit full scale). Peak 6 (MT-Mlα), studied in the present
work, was analyzed by mass spectrometry (ESI+). Charge states are annotated above each ion. Insert: deconvoluted spectrum and calculated molecular mass.
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equilibrium dissociation constant (KD) and the binding capacity
(Bmax) were determined from Scatchard plot (Munson and Rodbard,
1980). The inhibition constant (Ki) was determined from competition
curves using the Cheng and Prusoff equation (Cheng and Prusoff,
1973). The potency of the antagonist was expressed by the negative
logarithm of their Ki value (pKi).
Measurement of total [3H]inositol phosphate
Hippocampi were isolated from rats, and washed with a nutrient
solution of the following composition (mM): NaCl 118.00; KCl 4.78;
CaCl2 2.43; MgSO4 1.16; NaHCO3 23.80; KH2PO4 1.17; glucose 2.92
(pH 7.4). Hippocampus slices (100 mg of tissue) were allowed to
equilibrate for 10 min in nutrient solution at 37°Cunder constant shaking.
The slices were incubated for 40 minwith 1 μCi myo[3H]inositol (speciﬁc
activity 47.0 Ci/mmol; New England Nuclear, Boston, MA, USA), and for
an additional 30 min with 10 mM lithium chloride with myo[3H]inositol.
Tissues were then incubated in the absence (basal level) and presence of
carbachol (CCh, 10−8 to 10−4 M) (Sigma) for 40 min. MT-Mlα and
muscarinic antagonist pirenzepine (Sigma) were added 5 min prior to
incubation with CCh. Tissues were washed three times with nutrient
solution, transferred to 2 ml of methanol:chloroform (2:1 v/v) at 4°C
and homogenized with a Ultra-Turrax T25 homogenizer at 9,500 rpm.
Chloroform (0.62 ml) and H2O (0.93 ml) were added to the homogenate,
and the solutionwas centrifuged for 10 min at 2,000 g and 4°C to separate
the aqueous and organic phases (Fox et al., 1985; Pereira et al., 2008).
Total [3H]inositol phosphate was measured as previously described
by Ascoli et al. (1989) with the following modiﬁcation. The aqueous
layer was mixed with 1 ml anion-exchange resin (Dowex AG-X8,
formate form, 200–400 mesh; Bio Rad Laboratories, Richmond, CA,
USA), allowed to equilibrate for 30 min at room temperature, andcentrifuged at 1000 g for 5 min at 4 °C. The resin was then washed
sequentially with myo-inositol (4 ml) and 5 mM sodium tetraborate/
60 mM sodium formate (2 ml). The resin was incubated for 30 min at
room temperature with 2 ml of 0.1 M formic acid/1 M ammonium
formate. The total [3H] inositol phosphate was eluted and placed in
scintillation vials containing OptiPhase HiSafe 3 (Perkin Elmer, Lough-
borough Leics, UK). The amount of radioactivity was determined in
scintillation β-counter (LS 6500 IC, Beckman). Total [3H] inositol
phosphate was expressed as dpm/mg tissue.
The data were expressed as percentage of the maximum response
to carbachol and analyzed by the interactive non-linear regression
analysis through the computer program GraphPad Prism. The IC50,
concentration that inhibits 50% of the agonist maximum response
was determined.Statistical analysis
Data were expressed as mean±S.E.M.. Data were analyzed by
ANOVA followed by Newman-Keuls test for multiple comparisons,
or by the two-tailed Student's t-test to compare a response between
two groups (Snedecor andCochran, 1980). P valuesb0.05were accepted
as signiﬁcant.Results
Isolation and puriﬁcation of the MT-Mlα protein
As shown in Fig. 1, the active component, MT-Mlα could be isolated
from the venom of M. lemniscatus after one single analytical RP-HPLC
run. From 10 mg of the crude venom, 180 μg of MT-Mlαwas obtained.
Fig. 3. Amino acid multiple sequence alignment. MT-Mlαwas aligned with the proteins
of the M. frontalis, M. pyrrhocryptus and M. surinamensis venom, which are available in
Data Banks. Shaded characters indicate conserved amino acid residues.
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Fig. 1 presents the RP-HPLC proﬁle of the isolation ofM. lemniscatus
venom. Peak-6 (MT-Mlα) was collected and had its molecular mass
assessed by ESI-MS. TheMSproﬁle presents themultiply charged species,
as well as the deconvoluted spectrum, with the calculated molecular
mass (7048.12±1.78 Da) printed besides the peak. Edman degradation
yielded the following sequence: Leu-Ile-Cys-Phe-Ile-Cys-Phe-Ser-Pro-
Thr-Ala-His (Fig. 2). This sequence was analyzed against the public pro-
tein data bank to check for similarities with known proteins. Statistically
signiﬁcant matches were identiﬁed with toxins from M. frontalis, M.
pyrrhocryptus and M. surinamensis venom, as presented in Fig. 3. The
sequence determination showed that the MT-Mlα exerts high similarity
to other neurotioxins such as weak neurotoxin E3, fromM. pyrrhocryptus
and Frontoxin-III from M. frontalis, these proteins belong to the three-
ﬁnger-like neurotoxins. In addition, the MT-Mlα presents some conser-
vative residues that are present in theM. surinamensis proteins.
[3H]QNB binding in the rat hippocampus
The binding of [3H]QNB to membranes of hippocampus frommale
rats was speciﬁc and saturable. Scatchard analysis of speciﬁc binding
ﬁtted best a one-site model (Fig. 4). An analysis of four experiments,
performed in duplicate, yielded dissociation constant (KD) of 0.88±0.13
nM and maximum number of binding sites (Bmax) of 1459.40±235.26
fmol/mg protein.
Effect of MT-Mlα on [3H]QNB binding in the rat hippocampus
The puriﬁed component MT-Mlα obtained from M. lemniscatus
snake venom displacement the [3H]QNB binding in hippocampus
from male rats. The Hill coefﬁcient (nH) differed signiﬁcantly from
unity (nH=0.33±0.06). Furthermore, the analysis indicated a statistical
preference for a two-site rather than one-site ﬁt for MT-Mlα. Thus, the
binding curve in competition experiments with MT-Mlαwas indicative
of two types of [3H]QNB-binding site with pKi values of 9.08±0.67 and
6.17±0.19, n=4 (Fig. 5). On the other hand, the Hill coefﬁcient forFig. 2. RP-HPLC proﬁle of MT-Mlα. Sample: ~50 μg of MT-Mla previously puriﬁed under t
A: 0.1% TFA, B: 90% ACN (in 0.1% TFA), Gradient: from 0 to100% solvent B in 30 min. Detecatropine (control) did not differ signiﬁcantly from unity (nH=0.91±
0.06) and the analysis indicated a statistical preference for a one-site
rather than two-site ﬁt with pKi of 8.96±0.08, n=4 (Fig. 5). The
peaks 1, 2, 3, 4 and 5 were also examined for their ability to compete
with [3H]QNB for its binding sites. However, they were not able to
displace the binding of the muscarinic ligand (data not shown).Effects of carbachol (CCh) and MT-Mlα on total [3H]inositol phosphate
accumulation
The basal level of the total [3H]inositol phosphate in rat hippocampus
was 73.75±6.15 dpm/mg tissue, n=12. The cholinergic agonist
carbachol (CCh, 10−8 M to 10−4 M) caused a dose-dependent increase
of total hippocampal [3H]inositol phosphate frommale rats (Fig. 4). The
EC50 value for CCh was 830 nM in hippocampi. The maximum inositol
phosphate accumulation was obtained with 10−5 M CCh (35.91±
5.51% above basal, n=8) (Fig. 6A).
The puriﬁed component MT-Mlα (10-9 M to 10-6 M) obtained
from M. lemniscatus snake venom caused a dose-dependent blocked
on total [3H]inositol phosphate accumulation induced by 10−5 M
CCh in hippocampus from male rats (Fig. 6B). The IC50 value for
MT-Mlα was 33.1 nM.he same conditions. Column: C-18 (SUPELCOSIL-LC-18-DB 15 cm×4.6 mm). Solvents
tion: 214 nm. Flow: 1.0 mL/min.
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935D.C. da Silva et al. / Life Sciences 89 (2011) 931–938The M1 antagonist pirenzepine (10−9 M to 10−6 M) also caused a
dose-dependent blockage on total [3H]inositol phosphate accumulation
induced by 10−5 M CCh in hippocampus from male rats (Fig. 6B). The
IC50 value for pirenzepine was 2.26 nM.
In the absence of CCh, the MT-Mlα (10−6 M) and pirenzepine
(10−6 M) did not alter the level of total [3H]inositol phosphate in
the hippocampus (data not shown).
Discussion
The molecular mass of the MT-Mlα determined by ESI-MS in the
range of 7 KDa, is typically found in neurotoxins that belong to the
Micrurus (Olamendi-Portugal et al., 2008) and Dendroaspis (Ségalas-12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2
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Fig. 5. Displacement curves of [3H]QNB bound to hippocampus membranes from male
rats, induced by MT-Mlα and mAChR antagonist atropine. The data are plotted as
percentages of the binding in the absence of MT-Mlα or atropine. Each point and vertical
line represents the mean±S.E.M. of four different experiment, performed in duplicate.et al., 1995) genera. The partial sequence analyses generated with
the new data allowed to bridge a link among the various venom com-
ponents of other Elapidae containing the three-ﬁnger structures. The
sequence determination showed that the MT-Mlα exerts high simi-
larity to other neurotioxins such as weak neurotoxin E3, fromM. pyr-
rhocryptus and Frontoxin-III (FTx-III) from M. frontalis, these proteins
belong to the three-ﬁnger-like neurotoxins. Besides, the Ile in the
second position and the aromatic residue found in the 4th position
are conservative residues, which are also present in the musccarinic
toxin, Ms-3. The Cys6 is conserved in Ms-2, Ms-4 and Ms-5. More-
over, the Ser8 present in MT-Mlα is similar to the Tyr8 found in
Ms-2, Ms-3 and Ms-5. However, from position 9 on, the MT-Mlα
presents unique features not found in other MT.
Despite MT-Mlα presents similarity to FTx-III, that act on nicotinic
acetylcholine receptors (Moreira et al., 2010), we demonstrated in
the present work that the MT-Mlα was able to interact on mAChRs.
Furthermore, it is important to point out that the ability of the
Frontoxins to displace the binding of a muscarinic ligand was not
investigated for the authors. In addition, we can ﬁnd in the literature
the m2-toxin that displays a sequence more homologous to nicotinic
toxins than MTs but interacts more selectively on M2 receptor when
compared with other subtypes (Carsi et al., 1999). In this way, it was
also reported that the toxin WTX isolated from Naja kaouthia venom
interacts with both nicotinic and muscarinic acetylcholine receptors
(Mordvintsev et al., 2009). Whether the MT-Mlα plays a role on
nicotinic receptors remain to be explored.
The results of the present study show, for the ﬁrst time, that
mAChRs function is drastically affected by MT-Mlα, obtained from
Brazilian snake M. lemniscatus venom, since the inhibition of the
binding of the selective muscarinic ligand [3H]QNB and inhibition of
the [3H]inositol phosphate accumulation in hippocampuswere affected
936 D.C. da Silva et al. / Life Sciences 89 (2011) 931–938by toxin and may make the MT-Mlα a novel pharmacological tool to
examine the function of mAChRs.
[3H]QNB saturation binding studies indicated the presence of one
class of speciﬁc binding sites in rat hippocampus. The KD value
obtained in the hippocampus from male rats (0.88±0.13 nM) was
within the values reported by literature in different tissues
(KD=0.30–1.00 nM) that express mAChR such as, hypothalamus
(Avissar et al., 1981; Dohanich et al., 1982), preoptic area, caudate
putamen (Dohanich et al., 1982), cortex (Van Huizen et al., 1994) and
hippocampus (Cardoso et al., 2004) of rats. In order to characterize
the effect of MT-Mlα in these receptors, different concentrations of
the MT-Mlα component, obtained from M. lemniscatus venom, were
examined for their ability to compete with [3H]QNB for its binding
sites. The binding curve in competition experiments with MT-Mlα
was indicative of two types of [3H]QNB-binding site with pKi values of
9.08±0.67 and 6.17±0.19, suggesting that various mAChR subtypes
may be the target proteins of MT-Mlα. It is possible to ﬁnd in the
literature description for mucarinic toxins with this feature. Indeed,
the MT1, MT2 and MT4 toxins obtained from Dendroaspis angusticeps
venom recognize theM1 andM4 receptors with similar afﬁnity, binding
the three other receptor subtypes with a lower afﬁnity (see Karlsson et
al., 2000, for review). Some toxins interact with the different mAChR
subtypes with modest selectivity such as MTα and MTβ, isolated from
Dendroaspis polylepis, with a slightly higher preference for the M3, M4
and M5 subtypes than for M1 and M2 (see Karlsson et al., 2000, for
review). To validate the competition assay, the non-selectivemuscarinic
antagonist atropine was used as a positive control. The pKi value for
atropine (8.96±0.08) obtained in the present study are similar to
those reported in the literature in binding studies on cloned m1 to m5
mAChR (Dong et al., 1995). To analyze the subtype selectivity of the
MT-Mlα for the various mAChRs, further experimental approaches
like cloned m1-m5 receptors will be important in order to clarify the
mAChR subtypes involved in the effect of MT-Mlα. Furthermore, an
activity in allosteric site might also be considered since muscarinic
toxins that present a variety of functional characteristics such as allosteric
modulator has been described (see Servent and Fruchart-Gaillard, 2009,
for review).
Immunoprecipitation studies conﬁrmed that although hippocampus
expresses all mAChR subtypes, the population of M1 receptors is
predominant. In addition, the amount of M2 in the hippocampus is
higher than the amount of M3, M4 and M5 mAChRs (Levey, 1993; Oki
et al., 2005; Cardoso et al., 2010). The roles of subtypes of mAChR (see
Levey et al., 1995; Oki et al., 2005 for reviews) in hippocampal function
remain to be explored. Pharmacological evidences suggest that the
M1 receptor may mediate the cognition-enhancing effects of acetyl-
choline (Coyle et al., 1983; Mash et al., 1985; Quirion et al., 1989)
and hippocampal synaptic plasticity (Shinoe et al., 2005). The stimu-
lation of these receptors causes hydrolysis of phosphatidylinositol
4,5-bisphosphate (PIP2), producing inositol 1,4,5-triphosphate (IP3)
and diacylglycerol (DAG), an action mediated by the enzyme phos-
pholipase Cβ (PLCβ) (Nash et al., 2004; Porter et al., 2002; Willets
et al., 2004). IP3 receptors may mediate the propagation of Ca2+
waves in hippocampal dendrites induced by activation of mAChRs
(Power and Sah, 2002). In in vitro functional studies, the agonist or
antagonist properties of four muscarinic toxins (MT1, MT2, MT3 and
MT7) were investigated through the determination of their effects
on 35S-GTPγS binding, [3H]inositol phosphate accumulation, and
Ca2+ release or adenylate cyclase activity (see Servent and
Fruchart-Gaillard, 2009, for review). Functional studies not only pro-
vide information as to whether the MT-Mlα is an agonist or antagonist
but also the mechanisms on which muscarinic receptor subtypes the
MT-Mlα interact. Since in the rat hippocampus the population of
M1 receptors is predominant, in the present study, we have focused
only the PLC-mediated phosphoinositide hydrolysis in hippocampal
tissue, using pirenzepine, a selective antagonist for M1 subtype.
Carbachol caused a dose-dependent increase of total [3H] inositolphosphate accumulation in rat hippocampus indicating that mAChRs
are involved in this intracellular signaling pathway. The MT-Mlα
component obtained from M. lemniscatus venom, dose-dependent,
reduced the response to carbachol on total [3H]inositol phosphate
accumulation. In addition, in the absence of carbachol, 1 μM
MT-Mlα did not alter the level of total [3H]inositol phosphate.
Taken together, these studies suggest that the MT-Mlα has antagonist
effect on mAChRs in rat hippocampus. Moreover, the M1 antagonist
pirenzepine had a much higher potency on carbachol-induced increase
of total [3H]inositol phosphate (2.26 nM) when compared with the
obtained from MT-Mlα component (33.1 nM). This result suggests
that MT-Mlα has a lower afﬁnity for M1 subtype mediated by [3H]
inositol phosphate accumulation. Similar results were reported by
Olianas et al. (1996) in rat cerebral cortical membranes prelabelled
with [3H]-myoinositol. MT3 inhibited the methacholine-induced
[3H]-inositol phosphates formation with lower afﬁnity (113 nM)
when compared with pirenzepine (10.9 nM). On the other hand,
MT3 is a potent antagonist of the striatal muscarinic receptors
coupled to inhibition of adenylyl cyclase activity indicating a selective
for M4 subtype since the weaker potency of MT3 in antagonizing the
muscarinic responses in cerebral cortex and in the heart are consistent
with the reported lower afﬁnity of the toxin for the cloned ml and m2
receptor subtypes, respectively (Olianas et al., 1996). It is important to
emphasize that functional approaches to identify the speciﬁc mAChR
subtype involved in an effect are complex, due to the fact thatmuscarinic
ligands with high speciﬁcity for each receptor subtype are not available
at present (Caulﬁeld and Birdsall, 1998). Whether the MT-Mlα
component plays a role in other intracellular signaling pathways
coupled to mAChRs remains to be explored.
In addition to modulating pyramidal neuron excitability by inter-
acting withM1 receptors, mAChR activation inhibits glutamate release
at the Schaffer-collateral synapse (Fernandez de Sevilla and Buno,
2003; Hasselmo and Schnell, 1994). Recently studies have shown M4
receptors as mediating cholinergic suppression of glutamate release
(Shirey et al., 2008; Dasari and Gulledge, 2011). The dysfunction of
mAChRs in the central nervous system is associated with various
neurological diseases such as Alzheimer's disease, Parkinson's disease,
schizophrenia, and psychosis. For example, in Parkinson's disease,
anticholinergic drugs have been empirically used before the discovery
of L-DOPA whereas the potential role of M4 antagonists in restoring
the dopamine-acetylcholine balance has been postulated only recently
(Langmead et al., 2008). In addition, the muscarinic M4 receptor may
also play a role in the aetiology of psychosis (Teaktong et al., 2005),
and early data showed that the mixed M1/M4 agonist, xanomaline,
exerted antipsychotic effects in monkeys (Andersen et al., 2003).
Concerning the M1/M4 speciﬁcity, the literature has shown toxins
(Bradley, 2000; Jerusalinsky et al., 1997) and small molecule agents
(Langmead et al., 2006; Chan et al., 2008; Shirey et al., 2008) that
act on these receptors. This way, the afﬁnities of the MTs for native
muscarinic receptors have been investigated. MT1 and MT2 toxins
presented high afﬁnity for the muscarinic receptors in the hippo-
campus (M1), the cortex (M1 and M4), and the striatum (M4). No
interaction with the M3 muscarinic receptors in the rat pancreas
was observed. The above studies showed that MT1 and MT2 had
higher speciﬁcity for the M1 and M4 muscarinic receptors than M2,
M3, or M5 (Jerusalinsky et al., 1997). In this context, MT-Mlα can
be considered a new pharmacological tool to help in the knowledge
of the functional role, and roles in various diseases of the ﬁve
mAChR subtypes and the potential to the development of a new
therapeutic agent could as well be considered.
In conclusion, due to unique sequence characteristics of the
MT-Mlα, this protein can be considered to be a new member in this
group, although further analyses would be necessary to determine
the whole amino acid sequence and to assess whether MT-Mlα
would be really an antagonist on themuscarinic acetylcholine receptors.
In this way, studies using selective muscarinic antagonists, cloned
937D.C. da Silva et al. / Life Sciences 89 (2011) 931–938muscarinic receptors transfected into CHO cells, preparations of isolated
organs and behavioral studies of learning andmemory are in progress in
our laboratory.
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